Literature DB >> 16756635

Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis.

Rebecca Wing-Yan Chan1, Fernand Mac-Moune Lai, Edmund Kwok-Ming Li, Lai-Shan Tam, Kai-Ming Chow, Philip Kam-Tao Li, Cheuk-Chun Szeto.   

Abstract

BACKGROUND: Lupus nephritis is characterized by intra-renal inflammation. Patients with systemic lupus erythematosus (SLE) showed abnormal T-cell expression of RANTES (regulated upon activation, normal T cell expressed) and its level in their serum. The authors studied the mRNA expression of RANTES in the urinary sediment of lupus patients.
METHODS: The authors studied 88 lupus patients, who were classified into active, remission and non-renal SLE groups according to the disease activity, 29 non-SLE and 10 healthy controls. Lupus activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Urinary mRNA expression of RANTES was studied by real-time quantitative polymerase chain reaction.
RESULTS: The expression of RANTES in urinary sediment was significantly elevated in active group (P < 0.001). Expression level of RANTES correlated with the SLEDAI score (r = 0.57; P < 0.001) and renal score in SLEDAI (r = 0.60; P < 0.001). In addition, urinary expression of RANTES had significant correlation with degree of proteinuria, serum creatinine, albumin and estimated glomerular filtration rate.
CONCLUSION: The authors conclude that the mRNA expression of RANTES was elevated in the urinary sediment of patients with active lupus nephritis. Measurement of urinary mRNA expression may be a novel non-invasive method for the assessment of lupus disease activity and the severity of renal involvement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16756635     DOI: 10.1111/j.1440-1797.2006.00565.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  8 in total

1.  RANTES deficiency attenuates autoantibody-induced glomerulonephritis.

Authors:  Chun Xie; Kui Liu; Yuyang Fu; Xiangmei Qin; Geetha Jonnala; Tao Wang; Hong W Wang; Michael Maldonado; Xin J Zhou; Chandra Mohan
Journal:  J Clin Immunol       Date:  2010-10-01       Impact factor: 8.317

Review 2.  Mechanisms of disease: regulation of RANTES (CCL5) in renal disease.

Authors:  Alan M Krensky; Yong-Tae Ahn
Journal:  Nat Clin Pract Nephrol       Date:  2007-03

3.  Association of RANTES and MBL gene polymorphisms with systemic lupus erythematosus: a meta-analysis.

Authors:  Wang-Dong Xu; Hui Peng; Mo Zhou; Min Zhang; Bao-Zhu Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

4.  Expression of mRNA for functional molecules in urinary sediment in glomerulonephritis.

Authors:  Koji Tsugawa; Eishin Oki; Koichi Suzuki; Tadaatsu Imaizumi; Etsuro Ito; Hiroshi Tanaka
Journal:  Pediatr Nephrol       Date:  2007-12-19       Impact factor: 3.714

5.  Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.

Authors:  Yumin Xia; Sean R Campbell; Anna Broder; Leal Herlitz; Maria Abadi; Ping Wu; Jennifer S Michaelson; Linda C Burkly; Chaim Putterman
Journal:  Clin Immunol       Date:  2012-08-20       Impact factor: 3.969

6.  Differential expression of functional Fc-receptors and additional immune complex receptors on mouse kidney cells.

Authors:  Adisak Suwanichkul; Scott E Wenderfer
Journal:  Mol Immunol       Date:  2013-08-01       Impact factor: 4.407

7.  Tumor necrosis factor-α synergistically enhances polyinosinic-polycytidylic acid-induced toll-like receptor 3 signaling in cultured normal human mesangial cells: possible involvement in the pathogenesis of lupus nephritis.

Authors:  Tadaatsu Imaizumi; Tomomi Aizawa; Ryo Hayakari; Fei Xing; Pengfei Meng; Kazushi Tsuruga; Tomoh Matsumiya; Hidemi Yoshida; Liang Wang; Tetsuya Tatsuta; Hiroshi Tanaka
Journal:  Clin Exp Nephrol       Date:  2014-03-14       Impact factor: 2.801

8.  Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.

Authors:  Shahrad Taheri; Muhammad Asim; Hassan Al Malki; Omar Fituri; Manikkam Suthanthiran; Phyllis August
Journal:  Trials       Date:  2018-04-17       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.